

DAFTAR PUSTAKA

1. J Bolívar J. Essential Hypertension: An Approach to Its Etiology and Neurogenic Pathophysiology. *Int J Hypertens*. 2013;2013:547809.
2. Phipps E, Prasanna D, Brima W, Jim B. Preeclampsia: Updates in pathogenesis, definitions, and guidelines. *Clin J Am Soc Nephrol*. 2016;11(6):1102–13.
3. Gathiram P, Moodley J. Pre-eclampsia: its pathogenesis and pathophysiology. *Cardiovasc J Afr*. 2016;27(2):71–8.
4. Mayrink J, Costa ML, Cecatti JG. Preeclampsia in 2018: Revisiting Concepts, Physiopathology, and Prediction. *Sci World J*. 2018;2018.
5. Manrique C, Lastra G, Gardner M, Sowers JR. The Renin Angiotensin Aldosterone System in Hypertension: Roles of Insulin Resistance and Oxidative Stress. *Med Clin North Am*. 2009;93(3):569–82.
6. Goodwin JE, Geller DS. Glucocorticoid-induced hypertension. *Pediatr Nephrol*. 2012;27(7):1059–66.
7. Yuliandra Y, Armenia N, Arifin H. Efek Antihipertensi Tumbuhan Tali Putri (*Cassytha filiformis* L.) pada Tikus Hipertensi Yang Diinduksi Prednison dan Garam. *Semin Nas Perkemb Terkini Sains Farm dan Klin III*. 2013;264–70.
8. Armenia A, Yuliandra Y, Sattar MZA. Comparative effectiveness of defatted hypotensive crude extract, ethyl acetate and butanolic fractions of *Cassytha filiformis* L. on different models of hypertensive rats. *World J Pharm Pharm Sci*. 2014;3(12):200–8.
9. Yuliandra Y, Armenia A, Arifin H. Antihypertensive and antioxidant activity of *Cassytha filiformis* L.: A correlative study. *Asian Pac J Trop Biomed*. 2017;7(7):614–8.
10. Podjarny E, Losonczy G, Baylis C. Animal models of preeclampsia. *Semin Nephrol*. 2004;24(6 SPEC.ISS.):596–606.
11. Fushima T, Sekimoto A, Minato T, Ito T, Oe Y, Kisu K, et al. Reduced uterine perfusion pressure (RUPP) model of preeclampsia in Mice. *PLoS One*. 2016;11(5):1–12.

12. Seki H. Animal models of preeclampsia: an examination of usefulness and limitations based on the metabolic domino theory. *Hypertens Res Pregnancy*. 2018;5(2):52–8.
13. Pridjian G. Beneficial Effects of Metolazone in a Rat Model of Preeclampsia. *J Pharmacol Exp Ther*. 2006;318(3):1027–32.
14. March DJ, Planas E. *La litografia a Catalunya*. 1997;147–60.
15. IFPMA. Hypertension: Putting the pressure on the silent killer. *Int Fed Pharm Manuf Assoc*. 2016;(May).
16. Bansal SK, Goel D, Saxena V, Kandpal SD, Gray WK, Walker RW. The prevalence of hypertension and hypertension risk factors in a rural Indian community: A prospective door-to-door study. *J Cardiovasc Dis Res*. 2012;3(2):117–23.
17. Badan Penelitian dan Pengembangan Kesehatan Kementerian Kesehatan RI. *Riset Kesehatan Dasar*. In 2013.
18. Fatmawati L, Sulistyono A, Notobroto HB. Pengaruh Status Kesehatan Ibu Terhadap Derajat Preeklampsia / Eklampsia Di Kabupaten Gresik. *Bul Penelit Sist Kesehat*. 2017;20(2):52–8.
19. Siyad.A.R. Hypertension, *H.J.D.Med.vol.3* (1), April-October 2011, pp.1-16. *HJDMed.vol3* (1), April. 2011;3(1):1–16.
20. Dipro T., Wells G. *pharmachoterapy handbook seven edition*. seven edit. United Stated of America: The McGraw-Hill Companies; 2009.
21. Mayet J, Hughes A. Pathophysiology in hypertension. *Hear J* [Internet]. 2003;89:1104–1109. Available from: www.heartjnl.com
22. Gordan R, Gwathmey JK, Xie L-H. Autonomic and endocrine control of cardiovascular function. *World J Cardiol*. 2015;7(4):204.
23. Oparil S, Zaman MA, Calhoun DA. Review Pathogenesis of Hypertension. *Physiilogy Med A Ser Artic Link Medici ne With Sci*. 2003;139(9):761–76.
24. Ruland S, Aiyagari V. Cerebral autoregulation and blood pressure lowering. *Hypertension*. 2007;49(5):977–8.
25. De Simone G, Devereux RB, Chinali M, Best LG, Lee ET, Welty TK. Association of blood pressure with blood viscosity in American Indians: The

- Strong Heart Study. *Hypertension*. 2005;45(4):625–30.
26. Armstrong C. Practice Guidelines JNC 8 Guidelines for the Management of Hypertension AAFP 's " Five Key Metrics for Financial Success ." *Am Fam Physician*. 2014;90(7):503–4.
 27. Katzung BG. *Farmakologi dasar dan klinik*. 10th ed. jakarta: EGC; 2010.
 28. Jeyabalan A. Epidemiology of preeclampsia: Impact of obesity. *Nutr Rev*. 2013;71(SUPPL1).
 29. Ghulmiyyah L, Sibai B. Maternal Mortality From Preeclampsia/Eclampsia. *Semin Perinatol*. 2012;36(1):56–9.
 30. Nakimuli A, Chazara O, Byamugisha J, Elliott AM, Kaleebu P, Mirembe F, et al. Pregnancy, parturition and preeclampsia in women of African ancestry. *Am J Obstet Gynecol*. 2014;210(6):1–12.
 31. Ye C, Ruan Y, Zou L, Li G, Li C, Chen Y, et al. The 2011 survey on hypertensive disorders of pregnancy (HDP) in China: Prevalence, risk factors, complications, pregnancy and perinatal outcomes. *PLoS One*. 2014;9(6).
 32. Valenzuela FJ, Pérez-Sepúlveda A, Torres MJ, Correa P, Repetto GM, Illanes SE. Pathogenesis of preeclampsia: The genetic component. *J Pregnancy*. 2012;2012.
 33. Gupte S, Wagh G. Preeclampsia–Eclampsia. *J Obstet Gynecol India*. 2014;64(1):4–13.
 34. Schoenaker, Danielle AJM, Soedamah-muthu, Sabita S, Mishra, Gita D. The association between dietary factors and gestational hypertension and pre-eclampsia : a systematic review and meta-analysis of observational studies. *BMC Med*. 2014;12(157):1–18.
 35. Matsubara K, Higaki T, Matsubara Y, Nawa A. Nitric oxide and reactive oxygen species in the pathogenesis of preeclampsia. *Int J Mol Sci*. 2015;16(3):4600–14.
 36. Naljayan M V., Karumanchi SA. New Developments in the Pathogenesis of Preeclampsia. *Adv Chronic Kidney Dis*. 2013;20(3):265–70.
 37. Noris M, Perico N, Remuzzi G. Mechanisms of disease: Pre-eclampsia. *Nat Clin Pract Nephrol*. 2005;1(2):98–114.
 38. Kattah AG, Garovic VD. The Management of Hypertension in Pregnancy. *Adv*

- Chronic Kidney Dis. 2013;20(3):229–39.
39. Brown CM, Garovic VD. Drug treatment of hypertension in pregnancy. *Drugs*. 2014;74(3):283–96.
 40. Genest DS, Falcao S, Gutkowska J, Lavoie JL. Impact of exercise training on preeclampsia: Potential preventive mechanisms. *Hypertension*. 2012;60(5):1104–9.
 41. Ianosi-Irimie M, Vu H, Whitbred J, Pridjian C, Nadig J, Williams M, et al. A rat model of preeclampsia. *Clin Exp Hypertens*. 2005;27(8):605–17.
 42. Erlandsson L, Nääv Å, Hennessy A, Vaiman D, Gram M, Åkerström B, et al. Inventory of Novel Animal Models Addressing Etiology of Preeclampsia in the Development of New Therapeutic/Intervention Opportunities. *Am J Reprod Immunol*. 2016;75(3):402–10.
 43. Li J, LaMarca B, Reckelhoff JF. A model of preeclampsia in rats: the reduced uterine perfusion pressure (RUPP) model. *Am J Physiol Circ Physiol*. 2012;303(1):H1–8.
 44. DiPetrillo K. Cardiovascular genomics: methods and protocols. Vol. 53, *Journal of Chemical Information and Modeling*. East Hanover: Humana Press; 2009. 1–350 p.
 45. Mambatta A, Rashme V, Menon S, Jayarajan J, Harini S, Kuppusamy J. Reliability of dipstick assay in predicting urinary tract infection. *J Fam Med Prim Care*. 2015;4(2):265.
 46. Akcilar R, Turgut S, Caner V, Akcilar A, Ayada C, Elmas L, et al. Apelin effects on blood pressure and RAS in DOCA-salt-induced hypertensive rats. *Clin Exp Hypertens*. 2013;35(7):550–7.
 47. Zhang Y, Croft KD, Mori TA, Schyvens CG, McKenzie KUS, Whitworth JA. The antioxidant tempol prevents and partially reverses dexamethasone- induced hypertension in the rat. *Am J Hypertens*. 2004;17(3):260–5.
 48. Sandi C. Novelty-related rapid locomotor effects of corticosterone in rats. *Eur J Neurosci*. 1996;8(4):794–800.
 49. Erdely A, Freshour G, Tain YL, Engels K, Baylis C. DOCA/NaCl-induced chronic kidney disease: A comparison of renal nitric oxide production in resistant and susceptible rat strains. *Am J Physiol - Ren Physiol*. 2007;292(1):192–7.

50. Choudhary A, Tripathi N. Role of FRIOS (free radical induced oxidative stress) in outcome of pregnancy induced hypertension cases. *Int J Reprod Contraception, Obstet Gynecol.* 2017;6(8):3287.
51. Bandoli G, Palmsten K, Forbess Smith CJ, Chambers CD. A Review of Systemic Corticosteroid Use in Pregnancy and the Risk of Select Pregnancy and Birth Outcomes. *Rheum Dis Clin North Am.* 2017;43(3):489–502.



